Jamaal El-Khal, MD
General Practice · Oroville, CANPI 1912161324
Payments from drug & device makers
Across 386 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$669
- AstraZeneca$574
- Novo Nordisk$561
- GSK$413
- Boehringer Ingelheim$362
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,546100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $2,068 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 56 | $669 |
| AstraZeneca | 25 | $574 |
| Novo Nordisk | 17 | $561 |
| GSK | 23 | $413 |
| Boehringer Ingelheim | 16 | $362 |
| Sunovion Pharmaceuticals Inc. | 21 | $275 |
| Merck | 15 | $259 |
| Lilly USA, LLC | 8 | $230 |
| Bayer | 11 | $208 |
| Optinose US, Inc. | 2 | $200 |
| Pfizer | 8 | $193 |
| Daiichi Sankyo Inc. | 8 | $176 |
| Idorsia Pharmaceuticals US Inc | 5 | $174 |
| Johnson & Johnson | 4 | $171 |
| Dexcom, Inc. | 5 | $170 |
| Mylan Specialty L.p. | 1 | $114 |
| Exact Sciences | 5 | $110 |
| Teva Pharmaceuticals USA, Inc. | 1 | $110 |
| Amarin Pharma, Inc. | 5 | $92 |
| Smith+Nephew | 1 | $69 |
| Eisai Inc. | 4 | $64 |
| Sanofi Pasteur Inc. | 3 | $64 |
| Amgen | 3 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $29 |
| Antares Pharma, Inc. | 1 | $19 |
| SK Life Science, Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,553 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $165,893 |
| OzempicSemaglutide | 86 | $140,275 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 60 | $85,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $75,066 |
| JardianceEmpagliflozin | 43 | $62,592 |
| GlyxambiEmpagliflozin/Linagliptin | 38 | $46,185 |
| XareltoRivaroxaban | 27 | $43,827 |
| SynjardyEmpagliflozin/Metformin Hcl | 27 | $34,464 |
| TrulicityDulaglutide | 22 | $33,251 |
| GemtesaVibegron | 24 | $31,346 |
| MounjaroTirzepatide | 19 | $29,465 |
| KerendiaFinerenone | 18 | $23,452 |
| FarxigaDapagliflozin Propanediol | 14 | $23,119 |
| EntrestoSacubitril/Valsartan | 11 | $19,814 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $14,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Jardiance, Glyxambi, Synjardy, Jentadueto | $362 | $237,943179 claims |
| PfizerEliquis | $193 | $165,893128 claims |
| Novo NordiskOzempic | $561 | $140,27586 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $413 | $100,22494 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $230 | $62,71641 claims |
| Johnson & JohnsonXarelto | $171 | $43,82727 claims |
| MerckJanumet, Belsomra | $259 | $26,48940 claims |
| BayerKerendia | $208 | $23,45218 claims |
| AstraZenecaFarxiga | $574 | $23,11914 claims |
| NovartisEntresto | $19 | $19,81411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Oroville
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.